DRugwatch BlogRSS 2.0

DRugwatch Blog > December 2011 > Following in the Footsteps of Multaq: Can Emerging Antiarrhythmic Drugs Address Key Unmet Needs in A

Following in the Footsteps of Multaq: Can Emerging Antiarrhythmic Drugs Address Key Unmet Needs in Atrial Fibrillation?

Matt KileenContributor: Matthew Killeen, Ph.D.

Multaq (Sanofi’s dronedarone) has had a turbulent time on the market since its launch in the United States in 2009. Given the high unmet need for safe and effective new drugs to maintain a normal sinus rhythm in AF patients, analysts had predicted peak year annual sales of up to $4 million for Multaq. However, a number of factors have restricted Multaq’s uptake thus far and will continue to limit its future commercial prospects.

Firstly, the key efficacy end point used in Multaq’s pivotal AF trial (the ATHENA study) was unconventional for this indication and we believe that the drug’s data failed to fully resonate with prescribers. This effect was compounded by Multaq’s modest efficacy on traditional antiarrhythmic measures, which interviewed thought leaders tell us is one of its key drawbacks. These issues aside, safety has been the watchword for Multaq in 2011 and we predict that one event in particular will have a major impact on the drug’s future outlook. While January witnessed a liver safety alert being issued by regulatory agencies, July saw the suspension of Multaq’s Phase III PALLAS trial in permanent AF patients; what was once seen as a strategic move to expand the drug’s share of the AF market, ended with alarming results – Multaq was shown to significantly increase the risk of mortality in patients with permanent AF compared to placebo. We expect that this event will be hard to overcome for Multaq despite the fact that very different patients were studied in the PALLAS trial compared to the drug’s earlier, successful, ATHENA study.

As the medical community begins to re-evaluate Multaq’s value proposition, what emerging therapies are in development for AF, and do they have the potential to address the remaining unmet need for safer and more effective antiarrhythmic drugs? In the sections below, I profile two key therapies that are in early stage development for AF.
  1. Oral vernakalant (Cardiome/Merck). The IV formulation of this new antiarrhythmic won approval in Europe last year (where it is marketed as Brinavess) for the acute cardioversion of AF. Oral vernakalant, on the other hand, remains in early clinical development. Cardiome had previously completed Phase II testing of oral vernakalant; however, Merck has since decided to study the drug in a new series of Phase I and II trials using higher doses. Although amiodarone’s high level of antiarrhythmic efficacy creates an important barrier to entry for emerging antiarrhythmic drugs for AF, we believe that oral vernakalant has the potential offer important benefits over existing treatment options.
  2. Vanoxerine (ChanRx). Vanoxerine was initially in clinical development for Parkinson’s disease and depression but recent preclinical studies have revealed its prominent antiarrhythmic effects. ChanRx, a startup company that was spun out from a CRO specializing in cardiac safety studies, recently announced that it had closed its Series A funding to advance IV vanoxerine through to Phase IIb development for AF cardioversion.

    Oral vanoxerine remains in preclinical development, but a recent study provided the first insight into its efficacy for AF; the drug terminated AF and atrial flutter in a disease model of AF and prevented the arrhythmias from being re-induced.

In the antiarrhythmic drug arena, 2011 has been a year of re-evaluation, by physicians and regulators, of Multaq’s risk-benefit profile. Nonetheless, the diverse AF pipeline holds great potential. In addition to oral vernakalant and vanoxerine, several other companies are developing novel agents for AF that we anticipate will provide important benefits to patients and propel growth of the AF market. In particular, atrial-specific antiarrhythmic drugs, that are in early stage clinical development by Xention and Bristol-Myers Squibb/Teijin, could have an unprecedented level of safety and, therefore, satisfy a major unmet need in AF.
Posted on: 12/12/2011 2:56:06 PM | with 0 comments


Tags: Cardiovascular, Matt Killeen

Trackback URL: http://decisionresources.com/trackback/01925af3-7791-4d5c-aed3-31736a830fd8/Following-in-the-Footsteps-of-Multaq--Can-Emerging-Antiarrhythmic-Drugs-Address-Key-Unmet-Needs-in-A.aspx?culture=en-us

Comments
Blog post currently doesn't have any comments.
Leave comment Subscribe



What is the abbreviation for Accountable Care Organization?

 

rss twitter linkedin

 

DRugwatch Blog

Quick insight on intriguing drug market developments from Decision Resources’ analysts.

Recent posts

Post title:
The Budgetary Impact of Diabetic Comorbidities in Brazil and Mexico - How Little is Being Done to Measure and Control It
Post date:
8/31/2015 10:48:39 AM
Post Summary:
The type 2 diabetes (T2D) therapy market is often tied to a high commercial opportunity. Indeed, when we look at key Latin American markets such as Brazil and Mexico -- each with over 14 million prevalent cases of T2D and growing, and Mexico with one of the highest prevalence rates in the world -- it is unsurprising that Brazil’s and Mexico’s total pharmaceutical market for type 2 diabetes rival the size of some of the more mature markets.

Post title:
2015 ESC Congress in London – Overview of Upcoming Hot Line Sessions
Post date:
7/2/2015 11:57:46 PM
Post Summary:
Conor WalshContributor: Conor Walsh M.Sc., Ph.D.
Topics: Conference Commentary, Cardiovascular

This year’s ESC congress will take place in the Excel Exhibition Centre in London, United Kingdom. The spotlight this year is “environment and the heart,” highlighting the many different kinds of interactions between the environment and cardiovascular diseases.

Post title:
FDA Approval for The Medicines Company’s Intravenous Antiplatelet Kengreal
Post date:
6/23/2015 1:22:54 PM
Post Summary:
Conor WalshContributors: Conor Walsh, M.Sc., Ph.D.
Topics: Cardiovascular

On June 22nd, 2015 the U.S. FDA approved Kengreal (cangrelor), the Medicines Company’s intravenous antiplatelet drug for use “as an adjunct to percutaneous coronary intervention (PCI) for reducing the risk of periprocedural myocardial infarction, repeat coronary revascularization, and stent thrombosis in patients in who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.”

Post title:
Hematological Malignancies: Are Immune Checkpoint Inhibitors Checking-in?
Post date:
6/17/2015 9:32:42 AM
Post Summary:
Contributor: Dana Gheorghe, Ph.D
Topics
: Conference Commentary, Oncology


Recent years have seen an added emphasis on the relationship between cancer and the activity of the immune system. Novel agents that aim to harness the immune system have already been approved in the U.S. for solid tumors (Bristol-Myers Squibb/Ono Pharmaceutical’s Opdivo [nivolumab] for NSCLC and malignant melanoma, and Merck & Co.’s Keytruda [pembrolizumab] for malignant melanoma), and are in development for a plethora of other oncology indications. Most of the development has been targeted towards solid tumors, but the potential of immune checkpoint inhibitors in hematological malignancies is becoming increasingly evident.

Post title:
Cardiovascular Outcomes Trials Answer Long-Asked Questions – But New Questions Arise
Post date:
6/12/2015 10:26:05 AM
Post Summary:
Contributor: Eamonn O'Connor, Ph.D.

The recent American Diabetes Association’s 75th Scientific Sessions in Boston saw the release of data from the ELIXA cardiovascular outcomes trial (CVOT) for lixisenatide (Sanofi/Zealand Pharma’s Lyxumia), the first such trial completed for the GLP-1 receptor agonist drug class. However, it was the publication of the data from the CVOT for sitagliptin (Merck’s Januvia/Ono’s Glactiv), known as TECOS1, that was most eagerly anticipated; this is because the previous CVOTs for saxagliptin (AstraZeneca’s Onglyza) and alogliptin (Takeda/Furiex’s Nesina/Vipidia) had raised significant concerns about a potential risk for increased rates of hospitalization due to heart failure. The results from TECOS therefore, were viewed as pivotal as to whether this risk was a feature specific to the DPP-IV inhibitor drug class.

Decision Resources Group brands include: